In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 171 to 180 of 213

Sort by

Keyword or reference number: Treating this as aRemove Keyword or reference number: Treating this as a filter

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]	Technology appraisal guidance	TBC
Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]	Technology appraisal guidance	TBC
Sacituzumab govitecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor [ID6375]	Technology appraisal guidance	TBC
Sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer with papillary tumours or carcinoma in situ untreated with BCG ID6454	Technology appraisal guidance	TBC
Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over [ID6284]	Technology appraisal guidance	17 December 2025
Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]	Technology appraisal guidance	TBC
Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options [ID6273]	Technology appraisal guidance	TBC
Semaglutide for treating moderate to advanced liver fibrosis (without cirrhosis) caused by metabolic dysfunction-associated steatohepatitis [ID6458]	Technology appraisal guidance	26 August 2026
Setmelanotide for treating acquired hypothalamic obesity in people 4 years and over ID6542	Technology appraisal guidance	10 February 2027
Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6440]	Technology appraisal guidance	TBC

Results per page

10
25
50
All